Bavarian Nordic A/S's latest marketcap:
As of 07/05/2025, Bavarian Nordic A/S's market capitalization has reached $2.12 B. According to our data, Bavarian Nordic A/S is the 5960th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 2.12 B |
| Revenue (ttm) | 980.19 M |
| Net Income (ttm) | 207.82 M |
| Shares Out | 77.84 M |
| EPS (ttm) | 2.61 |
| Forward PE | 11.25 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/22/2025 |
Bavarian Nordic A/S's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | kr2.12 B | -11.49% | 5960 |
| 12/30/2024 | kr14.88 B | 7.57% | 5576 |
| 12/29/2023 | kr13.83 B | -8.19% | 5534 |
| 12/30/2022 | kr15.06 B | -20.32% | 5106 |
| 12/30/2021 | kr18.9 B | 73.28% | 4856 |
| 12/30/2020 | kr10.91 B | 96.88% | 5716 |
| 12/30/2019 | kr5.54 B | 34.78% | 7637 |
| 12/28/2018 | kr4.11 B | -43.11% | 7967 |
| 12/29/2017 | kr7.23 B | -7.41% | 6502 |
| 12/30/2016 | kr7.81 B | -22.07% | 6120 |
Company Profile
About Bavarian Nordic A/S
Bavarian Nordic A/S is a biopharmaceutical company specializing in the development, manufacturing, and supply of life-saving vaccines. Established in 1992, the company is headquartered in Hellerup, Denmark, and operates globally across multiple regions.
Key Products
- Smallpox & Monkeypox Vaccines: Marketed under the names IMVAMUNE, IMVANEX, and JYNNEOS.
- Rabies Vaccine: Available as Rabipur/RabAvert for human use.
- Tick-Borne Encephalitis Vaccine: Sold under the brand name Encepur.
- Cholera Vaccine: Vaxchora, an oral immunization solution.
- Typhoid Fever Vaccine: Vivotif/Typhoral, an oral vaccine.
Pipeline Development
The company is actively developing MVA-BN WEV, a potential treatment for encephalitis viruses.
Global Operations
Bavarian Nordic A/S serves markets in the United States, Denmark, Canada, France, Germany, Singapore, Finland, the Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and other international locations.
Frequently Asked Questions
-
What is Bavarian Nordic A/S's (CPH-BAVA) current market cap?As of 07/05/2025, Bavarian Nordic A/S (including the parent company, if applicable) has an estimated market capitalization of $2.12 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Bavarian Nordic A/S (CPH-BAVA) rank globally by market cap?Bavarian Nordic A/S global market capitalization ranking is approximately 5960 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.